Daily Endocrinology Research Analysis
Three endocrinology papers stood out today: a meta-analysis of randomized trials shows bariatric surgery yields durable diabetes remission and reduces microvascular complications versus medical therapy; a randomized trial reports first-trimester probiotic and dietary fiber fermented milk halves gestational diabetes risk in overweight/obese women; and mixed-meal phenotyping reveals pancreatic cancer–related diabetes is metabolically distinct from type 2 diabetes, enabling diagnostic and therapeut
Summary
Three endocrinology papers stood out today: a meta-analysis of randomized trials shows bariatric surgery yields durable diabetes remission and reduces microvascular complications versus medical therapy; a randomized trial reports first-trimester probiotic and dietary fiber fermented milk halves gestational diabetes risk in overweight/obese women; and mixed-meal phenotyping reveals pancreatic cancer–related diabetes is metabolically distinct from type 2 diabetes, enabling diagnostic and therapeutic stratification.
Research Themes
- Metabolic surgery and diabetes remission/microvascular protection
- Microbiome-targeted prevention in gestational endocrinology
- Metabolic phenotyping to distinguish cancer-associated diabetes from type 2 diabetes
Selected Articles
1. Diabetes remission and diabetic complications of bariatric surgery vs. medical management in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Across randomized trials, bariatric surgery produced substantially higher diabetes remission than medical therapy at 1, 2, 3, and ≥5 years and reduced microvascular complications, especially albuminuria, without a clear effect on macrovascular events. Findings reinforce metabolic surgery as a durable disease-modifying therapy for type 2 diabetes.
Impact: This synthesis provides high-level evidence that bariatric surgery confers durable remission and microvascular benefits, informing guideline updates and multidisciplinary referral pathways.
Clinical Implications: Consider earlier referral of eligible patients with type 2 diabetes for metabolic surgery to achieve remission and reduce microvascular risk (e.g., albuminuria), while continuing aggressive management of macrovascular risk factors.
Key Findings
- Bariatric surgery achieved 53.1% diabetes remission at 1 year vs 5.4% with medical therapy (RR=8.26; 95% CI 4.69-14.56).
- Superiority for remission persisted at 2 years (RR=7.42), 3 years (RR=16.97), and ≥5 years (RR=4.26).
- Reduced microvascular events vs medical therapy (RR=0.42); albuminuria incidence reduced (RR=0.37).
- No statistically significant difference in macrovascular events (RR=1.09; 95% CI 0.70-1.70).
Methodological Strengths
- Meta-analysis restricted to randomized controlled trials with prespecified remission definitions.
- Assessment across multiple time horizons (1, 2, 3, and ≥5 years) and micro/macrovascular outcomes.
Limitations
- Heterogeneity across surgical procedures and trial sizes; some RCTs small.
- Macrovascular outcomes underpowered; potential publication and reporting biases not fully excluded.
Future Directions: Individual patient data meta-analyses to identify subgroups benefiting most, pragmatic trials comparing modern medical therapy (including GLP-1/GIP and SGLT2 combinations) versus surgery, and longer-term macrovascular outcomes.
AIM: Most randomized controlled trials (RCTs) of bariatric surgery have a small size, a limited type of surgical procedure, and follow-up duration. Our aim was to compare bariatric surgery with medical management in patients with type 2 diabetes mellitus (T2DM) based on a meta-analysis of RCTs. MATERIALS AND METHODS: PubMed/Medline, Embase, and the Cochrane Central Register of Controlled Trials were searched for studies published before February 28, 2025. We included RCTs comparing bariatric surgery with medical management in T
2. Probiotics and dietary fibre fermented milk supplementation initiated in the first trimester to prevent gestational diabetes mellitus in overweight and obese pregnant women: A randomized controlled trial.
In overweight/obese pregnant women, first-trimester probiotic and dietary fiber fermented milk reduced gestational diabetes by 55% versus standard care, while intensive diet/lifestyle counseling lowered weight gain without significantly reducing GDM. Microbiome correlations suggest mechanistic plausibility.
Impact: Repurposes a scalable, food-based intervention started early in pregnancy to prevent GDM in a high-risk population, with clinically meaningful effect size.
Clinical Implications: Consider adding standardized probiotic/fiber fermented milk in the first trimester for overweight/obese pregnant patients alongside routine antenatal care; monitor product quality/strain composition and integrate with diet and weight-gain counseling.
Key Findings
- PFM reduced GDM incidence to 18.42% vs 33.33% with standard care (OR=0.45; 95% CI 0.25-0.83).
- Intensive diet/lifestyle arm reduced median weight gain (4.0 kg) but did not significantly reduce GDM.
- Microbiome analyses: Acidovorax abundance (PFM group) inversely associated with fasting OGTT glucose; Megasphaera (standard care) positively associated with 2-h glucose.
Methodological Strengths
- Parallel randomized controlled design with first-trimester initiation in a high-risk cohort.
- Clinically relevant primary endpoint (GDM incidence) and exploratory microbiome correlations.
Limitations
- Group sizes unequal; blinding and allocation concealment not detailed in the abstract.
- Generalizability and durability beyond the OGTT timepoint not established; product standardization across settings needed.
Future Directions: Multicenter, blinded trials with standardized probiotic strains/doses, longer maternal-neonatal follow-up, and mechanistic studies linking taxa/metabolites to glucose metabolism.
AIMS: To evaluate the effects of intensive dietary and lifestyle (IDL) interventions and probiotic and dietary fibre fermented milk (PFM) supplementation, initiated in the first trimester, on the risk of gestational diabetes mellitus (GDM) and pregnancy outcomes in overweight and obese women. MATERIALS AND METHODS: In this parallel randomized controlled trial, 478 women with a prepregnancy body mass index ≥25 kg/m RESULTS: GDM incidence was 25.60% in the IDL group (32/125), 18.42% in the PFM group (21/114), and 33.33% in the SC group (39/117) (p = 0.035). PFM reduced GDM risk by 55% compared with SC (OR = 0.45, 95% CI: 0.25-0.83). At the time of the oral glucose tolerance test (OGTT), median weight gain was lower in the IDL group (4.00 kg) than in the PFM (5.20 kg) and SC (5.65 kg) groups (p = 0.009). Correlation analysis revealed that Acidovorax abundance in PFM was negatively associated with OGTT 0 h glucose, while Megasphaera in the SC group was positively correlated with 2-hour post-load glucose (p < 0.05). CONCLUSIONS: PFM supplementation initiated in the first trimester reduced GDM incidence. IDL reduced weight gain but had no significant effect on GDM. PFM may be a promising strategy for GDM prevention in these high-risk populations.
3. Pancreatic cancer-related diabetes and type 2 diabetes differ in multiple aspects of glucose homeostasis.
Using mixed-meal tolerance testing, PDAC-related diabetes showed markedly higher insulin sensitivity but profoundly reduced insulin secretion and beta cell function versus type 2 diabetes, along with higher insulin clearance and elevated postprandial glucagon and GLP-1. These signatures persisted after multivariable adjustment, supporting metabolic discrimination and potential diagnostic biomarker development.
Impact: Defines a reproducible metabolic phenotype that can distinguish PDAC-DM from type 2 diabetes, addressing delays in cancer detection and enabling individualized hyperglycaemia management.
Clinical Implications: In patients with new-onset diabetes and risk factors for pancreatic cancer, mixed-meal–derived indices (insulin secretion, clearance, glucagon/GLP-1 responses) may help differentiate PDAC-DM and guide insulin-centered management while prompting evaluation for underlying PDAC.
Key Findings
- PDAC-DM patients had ~2.5-fold higher insulin sensitivity than type 2 diabetes.
- Insulin secretion was ~81% lower and oral disposition index ~40% lower in PDAC-DM.
- Insulin clearance was higher in PDAC-DM independent of insulin sensitivity.
- Postprandial glucagon and GLP-1 were higher in PDAC-DM; GIP was similar.
- Differences persisted after adjustment for age, sex, and BMI.
Methodological Strengths
- Standardized mixed-meal tolerance testing with comprehensive hormone/metabolic indices.
- Multivariable adjustment for key confounders (age, sex, BMI).
Limitations
- Relatively small PDAC-DM sample size and cross-sectional physiology limits causal inference.
- Single-visit phenotyping; external validation and biomarker thresholds are needed.
Future Directions: Prospective validation in larger, multi-ethnic cohorts, integration into risk models for early PDAC detection, and interventional studies testing insulin-centric regimens in PDAC-DM.
AIMS/HYPOTHESIS: Pancreatic ductal adenocarcinoma-related diabetes mellitus (PDAC-DM) is a paraneoplastic syndrome with a poorly understood pathophysiology. PDAC-DM is often clinically confused with type 2 diabetes, resulting in delayed cancer detection and poorly individualised hyperglycaemia treatment. We investigated whether these forms of diabetes can be distinguished at the metabolic level. METHODS: Adults with either cancer treatment-naive PDAC-DM (n=28) or type 2 diabetes (n=97), and with diabetes onset within 3 years, underwent mixed-meal tolerance tests to investigate glucose metabolism. Outcomes included insulin sensitivity (Matsuda index), insulin secretion (insulinogenic index), beta cell function (oral disposition index), insulin clearance, and postprandial glucagon, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) responses. RESULTS: Compared with type 2 diabetes, individuals with PDAC-DM showed ~2.5-fold greater insulin sensitivity, ~81% lower insulin secretion and ~40% lower beta cell function. Insulin clearance was higher in the PDAC-DM group than the type 2 diabetes group, with and without adjustment for insulin sensitivity. Glucagon and GLP-1 levels increased after a meal in both groups, but levels were higher in the PDAC-DM group. GIP levels were similar between groups. The metabolic differences between groups persisted after adjustment for age, sex and BMI. CONCLUSIONS/INTERPRETATION: PDAC-DM and type 2 diabetes are metabolically distinct, with different defects responsible for hyperglycaemia. PDAC-DM is characterised predominantly by insulin deficiency and displays higher insulin sensitivity than type 2 diabetes. There are also differences in alpha cell regulation and insulin clearance compared with type 2 diabetes. These findings identify biological characteristics that may have implications for individualised treatment of PDAC-DM and guide diagnostic biomarker discovery for early PDAC diagnosis.